[PET in Neurology: Imaging Pathology, Metabolism, and Disease Progression]
{{output}}
Anti-amyloid-β therapies for Alzheimer's disease-lecanemab (Leqembi approved in September 2023) and donanemab (Kisunla®; approved in September 2024)-have been authorized in Japan and are now in clinical use. In parallel, amyloid positron emission tomography... ...
